Novian Health is a privately held, medical device company based in Chicago with a subsidiary in Evry, France. It has developed proprietary technology for the minimally invasive treatment of tumors using Interstitial Laser Therapy (ILT). Novilase® Breast Therapy uses parametrically controlled heating to ablate breast tumors under ultrasound or stereotactic x-ray image guidance. Founded by Dr. Kambiz Dowlat, a former professor of surgery at Rush University Medical Center in Chicago, who is a leading specialist in breast cancer diagnosis and treatment. Early on he recognized that imaging would be able to detect earlier stage tumors and that a minimally invasive alternative to traditional surgery would be beneficial for the treatment of small tumors (e.g., 2 cm or less in diameter). Based on Dr. Dowlat’s research, Novian Health received U.S. FDA 510(k) clearance for the laser ablation treatment of fibroadenomas, or benign breast tumors, and ablation of soft tissue. Approval for the treatment of malignant breast tumors will be sought following completion of current multi-center clinical trials in the U.S. and Europe that are evaluating Novilase for the treatment of small breast cancers. Other tumor sites and indications are also being explored. Novilase is a procedure that can be performed in an outpatient setting, offering potentially significant advantages over surgery including minimal scarring, quicker recovery times, and only requiring local anesthesia. Novilase may be performed by physicians (e.g., surgeons and radiologists) with experience in image-guided procedures (e.g., breast biopsies).